Genetic Mechanisms and Therapeutic Approaches in X-Linked Retinoschisis

X-linked retinoschisis is a monogenic retinal disorder caused by loss-of-function mutations in the RS1 gene, which encodes the extracellular protein retinoschisin. Retinoschisin normally assembles as a disulfide-linked octamer that stabilises retinal cell layers and maintains synaptic integrity between photoreceptors and bipolar cells. Pathogenic variants often disrupt discoidin domain folding or octamerisation, leading to endoplasmic reticulum stress, impaired secretion, abnormal cell adhesion and progressive splitting (schisis) of the inner retinal layers. Clinically, patients present with foveal schisis, reduced visual acuity and characteristic electroretinographic abnormalities. Over the past decade, therapeutic strategies have centred on gene augmentation using adeno-associated viral vectors to deliver a functional RS1 copy, alongside small-molecule approaches that mitigate chronic endoplasmic reticulum stress and downstream pro-apoptotic signalling. Preclinical studies in rodent models and patient-derived retinal organoids have demonstrated restoration of retinal architecture, improvement in synaptic transmission and rescue of visual function. Emerging technologies including multiomic profiling, non-viral delivery systems and precise genome editing are now refining target validation and optimising safety and efficacy profiles, offering renewed hope for durable treatment of this vision-threatening disease.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Genetic Mechanisms and Therapeutic Approaches in X-Linked Retinoschisis publication trend

The graph below shows the total number of articles in genetic mechanisms and therapeutic approaches in x-linked retinoschisis across all publications each year (not limited to Nature Index journals).

Technical terms

RS1 gene: The gene on the X chromosome encoding retinoschisin, mutations of which cause X-linked retinoschisis.

Retinoschisin: A discoidin domain-containing adhesion protein that assembles as an extracellular octamer to maintain retinal layer organisation and synaptic structure.

Adeno-associated virus (AAV): A non-pathogenic viral vector commonly used for in vivo gene delivery, including RS1 gene augmentation.

Retinal organoid: A three-dimensional, stem cell–derived tissue model that recapitulates key features of human retinal development and disease.

Electroretinography (ERG): A diagnostic test measuring electrical responses of retinal cells to light stimuli, used to assess functional rescue in preclinical models.

References

1. RS1, a Discoidin Domain-containing Retinal Cell Adhesion Protein Associated with X-linked Retinoschisis, Exists as a Novel Disulfide-linked Octamer*. Journal of Biological Chemistry (2005).
2. Defective Discoidin Domain Structure, Subunit Assembly, and Endoplasmic Reticulum Processing of Retinoschisin are Primary Mechanisms Responsible for X-linked Retinoschisis*. Journal of Biological Chemistry (2003).
3. X-Linked Retinoschisis Deep Phenotyping and Genetic Characterization. Ophthalmology (2021).
4. Identifying Multiomic Signatures of X‐Linked Retinoschisis‐Derived Retinal Organoids and Mice Harboring Patient‐Specific Mutation Using Spatiotemporal Single‐Cell Transcriptomics. Advanced Science (2024).
5. Retinal organoids with X-linked retinoschisis RS1 (E72K) mutation exhibit a photoreceptor developmental delay and are rescued by gene augmentation therapy. Stem Cell Research & Therapy (2024).
6. The Road towards Gene Therapy for X-Linked Juvenile Retinoschisis: A Systematic Review of Preclinical Gene Therapy in Cell-Based and Rodent Models of XLRS. International Journal of Molecular Sciences (2024).